Fig. 3: Efficacy of mCD19 CAR-T cell in murine lymphoma/leukemia model. | Cell Death & Disease

Fig. 3: Efficacy of mCD19 CAR-T cell in murine lymphoma/leukemia model.

From: The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma/leukemia

Fig. 3

A The survival of lymphoma mice following CAR-T cell treatment. The OS and PFS data were recorded from the day of CAR-T cell administration. Clinical scores were compared between mice treated with mCD19 CAR-T cells and a control group. B The timing of disease occurrence and response rate following anti-CD19 CAR T cell therapy was demonstrated. C The in vivo bioluminescent imaging of lymphoma-bearing mice injected with luciferase-expressing A20 cells and subsequently treated with CAR-T cells for 5 and 12 days. D The proportion of total CD19+ cells in BM on day 15. E Percentages of GFP+CD3+ CAR-T cells in BM, SP, and liver were quantified. Representative flow cytometry plots from 3 individual mice were presented. The log-rank test was employed to compare survival rates, and the t test was used to compare between two groups. One-way ANOVA was used for statistical analysis in (D and E). There were two independent experiments repeated. *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001.

Back to article page